AQP4 cohort | MOG cohort | |
Number of patients/number of patients with pregnancies after disease onset | 83/50 | 21/5 |
Number of informative pregnancies/number of pregnancies after disease onset | 108/66 | 21/5 |
Number of total pregnancy-related attacks | 126 | 28 |
Age at disease onset, year, mean±SD | 25.8±6.3 | 26.7±5.9 |
Age at delivery/abortion, year, mean±SD | 28.4±4.6 | 28.3±3.6 |
AQP4-ab or MOG-ab titre, median (range) | 1:32 (1:10–1:3200) | 1:32 (1:10–1:320) |
Number of pregnancy-related attacks (%) | ||
DP1 | 13 (10.3) | 2 (7.1) |
DP2 | 9 (7.1) | 1 (3.6) |
DP3 | 4 (3.2) | 0 (0) |
PP1 | 51 (40.5) | 11 (39.3) |
PP2 | 25 (19.8) | 5 (17.9) |
PP3+4 | 24 (19.0) | 9 (32.1) |
Number of different pregnancy outcomes or complications (%) | ||
Term delivery | 60 (55.6) | 18 (85.7) |
Premature delivery | 5 (4.6) | 1 (4.8) |
Elective abortion | 39 (36.1) | 2 (9.5) |
Spontaneous abortion | 4 (3.7) | 0 (0) |
Neonatal malformation | 3 (2.8) | 0 (0) |
Pre-eclampsia | 0 (0) | 0 (0) |
BP-ARR mean (95% CI) | 0.33 (0.19 to 0.47) | 0.40 (0.26 to 0.54) |
Adjusted BP-ARR* mean (95% CI) | 0.33 (0.26 to 0.41) | – |
PP-ARR mean (95% CI) | 0.65 (0.46 to 0.84) | 0.60 (0.38 to 0.82) |
Adjusted PP-ARR* mean (95% CI) | 0.69 (0.61 to 0.78) | – |
*ARR was adjusted using a Poisson regression for treatment variables (inadequate or adequate treatment) during 12–0 months prepregnancy and during 0–12 months after delivery/abortion.
AQP4-ab, aquaporin-4 antibody; ARR, annualised relapse rate; BP, before pregnancy; DP, during pregnancy; MOG-ab, myelin oligodendrocyte glycoprotein antibody; NMOSD, neuromyelitis optica spectrum disorder; PP, postpartum period.;